Genmab A/S
Denmark
435 articles about Genmab A/S
-
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
6/2/2021
Genmab A/S and Bolt Biotherapeutics, Inc. announced that the companies have entered into an oncology research and development collaboration.
-
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
5/21/2021
Company Announcement Janssen received a positive CHMP opinion for DARZALEX ® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed systemic light-chain (AL) amyloidosis Opinion based on data from the Phase 3 ANDROMEDA (AMY3001) study CHMP also issued a positive opinion recommending DARZALEX ®
-
Genmab Announces Financial Results for the First Quarter of 2021
5/5/2021
Genmab Interim Report for the First Quarter Ended March 31,2021
-
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
4/9/2021
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
-
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2/10/2021
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look. -
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
-
Clinical Catch-Up: October 19-23
10/26/2020
It was another busy week for clinical trial updates and news. Here’s a look. -
The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
In a brief statement, Genmab said it initiated binding arbitration related to two matters under its Darzalex (daratumumab) license agreement with Janssen Biotech.
-
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
9/21/2020
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an
-
AbbVie and Genmab Announce Broad Oncology Collaboration
6/10/2020
AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab
-
The collaboration will focus on the development of three of Genmab's bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
-
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
5/25/2020
Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens.
-
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
-
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
12/19/2019
Genmab A/S (Nasdaq: GMAB) and CureVac AG announced today that Genmab and CureVac have entered into a research collaboration and license agreement.
-
Genmab Announces Financial Results for the First Nine Months of 2019
11/6/2019
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs
-
Clinical Catch-Up: August 25-30
9/3/2019
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories. -
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.